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Abstract
Super-enhancers (SEs), which are composed of large clusters of enhancers densely loaded with the 
Mediator complex, transcription factors (TFs), and chromatin regulators, drive high expression of 
genes implicated in cell identity and disease, such as lineage-controlling TFs and oncogenes 1, 2. 
BRD4 and CDK7 are positive regulators of SE-mediated transcription3,4,5. In contrast, negative 
regulators of SE-associated genes have not been well described. Here we report that Mediator-
associated kinases cyclin-dependent kinase 8 (CDK8) and CDK19 restrain increased activation of 
key SE-associated genes in acute myeloid leukaemia (AML) cells. We determined that the natural 
product cortistatin A (CA) selectively inhibited Mediator kinases, had antileukaemic activity in 
vitro and in vivo, and disproportionately induced upregulation of SE-associated genes in CA-
sensitive AML cell lines but not in CA-insensitive cell lines. In AML cells, CA upregulated SE-
associated genes with tumour suppressor and lineage-controlling functions, including the TFs 
CEBPA, IRF8, IRF1 and ETV6 6, 7, 8. The BRD4 inhibitor I-BET151 downregulated these SE-
associated genes, yet also has antileukaemic activity. Individually increasing or decreasing 
expression of these TFs suppressed AML cell growth, providing evidence that leukaemia cells are 
sensitive to dosage of SE-associated genes. Our results demonstrate that Mediator kinases can 
negatively regulate SE-associated gene expression in specific cell types and can be 
pharmacologically targeted as a therapeutic approach to AML.
CDK8 associates with CCNC (Cyclin C), MED12, and MED13 to form a CDK8 module 
that can reversibly associate with the 26-subunit Mediator complex 9. Because SEs are 
disproportionately loaded with Mediator2, we examined whether CDK8, as a Mediator-
associated kinase, might regulate SE function. Using chromatin immunoprecipitation 
followed by sequencing (ChIP-seq), we mapped the genome-wide occupancy of CDK8, 
along with known SE-associated factors and histone modifications, in the AML cell line 
MOLM-14. Semi-supervised hierarchical clustering revealed that CDK8 most closely 
associated with MED1, followed by BRD4 and H3K27ac, at putative enhancer elements 
marked with H3K4me1 (red bar, Fig. 1a, Extended Data Fig. 1a-c). A fraction of these 
regions were particularly large and loaded with CDK8, MED1 and BRD4, suggesting they 
may represent SEs. Consistent with this notion, the majority of CDK8, MED1, BRD4 and 
H3K27ac ChIP-seq signal was disproportionately located on a small number of SEs 
identified by each factor separately (Extended Data Fig. 1d-f). These SEs significantly 
overlapped (Fig. 1b,c, Supplementary Table 1). Genes associated with these SEs were 
enriched with gene ontology (GO) terms pertinent to haematopoiesis, cellular 
differentiation, and transcription, supporting the notion that SEs regulate cellular identity 
(Supplementary Data Table 1).
To determine whether pharmacologic inhibition of Mediator kinases regulates SE function 
and inhibits AML proliferation, in analogy to BRD4, we characterized CA (Fig. 2a) as an 
inhibitor of CDK8 and its paralog CDK19 (77% identical overall and 94% in the catalytic 
domain). CA was reported to bind CDK8 and CDK19, as well as ROCK1 and ROCK2, as 
individual proteins in vitro10. We synthesized CA11,12 and determined that it potently 
inhibited the kinase activity of the CDK8 module in vitro (IC50 = 12 nM, Fig. 2b, Extended 
Data Fig. 2a). In contrast, CA did not inhibit other transcriptional cyclin-dependent kinases 
CDK7 (TFIIH), CDK9 (P-TEFb), CDK12, or CDK13 in vitro, nor did it bind CDK9, 
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CDK12, CDK13, ROCK1 or ROCK2 up to 2,500 nM in MOLM-14 cell lysate (Fig. 2b, 
Extended Data Fig. 2b,c). In cells, CA dose-dependently inhibited phosphorylation of 
known CDK8 substrates STAT1 S72713 (IC50 < 10 nM), Smad2 T220 and Smad3 T17914 
(IC50 < 100 nM) (Extended Data Fig. 2d). No kinase substrates have been reported for 
CDK19.
We more broadly evaluated CA selectivity in cell lysate (KiNativ)15 and in vitro, which 
collectively tested 387 kinases. At 100-times the CDK8 IC50, CA was fully selective in 
MOLM-14 cell lysate for CDK8/CDK19 and in vitro only inhibited CDK8/CCNC and 
GSG2, the latter of which we disqualified as a cellular target of CA (Fig. 2c, Extended Data 
Fig. 2c,e-h, Supplementary Table 2, Supplementary Information). CA also exhibited high 
affinity binding (Kd = 195 ± 15.8 pM), slow binding kinetics (koff = 6.35×10−5 ± 8.15×10−6 
s−1, kon = 3.26×105 ± 1.54×104 s−1M−1) and a long residence time (262 ± 34 min) in its 
interaction with CDK8/CCNC in vitro.
To understand how CA inhibits CDK8, we obtained a high-resolution (2.4 Å) crystal 
structure of a CA/CDK8/CCNC ternary complex (Fig. 2d, Extended Data Fig. 3). CA 
exhibits exquisite shape complementarity with the ATP-binding pocket of CDK8. In 
particular, the isoquinoline of CA forms N-H and CH-O hydrogen bonds with Ala 10016, the 
C5–C9 ethano bridge and the C13-methyl group of CA occupy deep hydrophobic crevices in 
the ATP-binding site, and the protonated C3 N,N-dimethylamine of CA engages in an 
apparent cation-π interaction with Trp 10517.
We investigated the antiproliferative activity of CA and observed that it inhibited the 
proliferation (GI50 < 10 nM) of several myeloid, mixed-lineage, and megakaryoblastic 
leukaemia cell lines harbouring diverse oncogenic contributors, including MLL-fusions 
(MOLM-14, MV4;11, and RS4;11), RUNX1-RUNX1T1 (SKNO-1), JAK2V617F (SET-2 and 
UKE-1) and BCR-ABL (MEG-01) (Fig. 2e, Extended Data Table 1, Extended Data Fig. 4a). 
CA inhibited CDK8 kinase activity in both sensitive and insensitive cell lines with similar 
potency and did not alter CDK8 or CDK19 protein levels (Extended Data Fig. 4b,c). 
Although SET-2 and HEL cell lines harbour the JAK2V617F mutation and MEG-01 and 
K562 harbour the BCR-ABL translocation, megakaryoblastic cell lines SET-2 and MEG-01 
cells were sensitive to CA whereas erythroleukaemia-derived cell lines HEL and K562 were 
not, suggesting that cell lineage may be a contributing determinant for CA sensitivity18. The 
phenotypic effects of CA were cell line-dependent. CA treatment increased megakaryocyte 
markers CD41 and CD61 on SET-2 cells, whereas CA treatment of MOLM-14, MV4;11, 
and SKNO-1 cells increased cleaved PARP levels, Annexin V staining and the sub-G1 cell 
population, consistent with apoptosis (Extended Data Fig. 4d-f).
We confirmed that Mediator kinases mediate the antiproliferative activity of CA by 
identifying a point mutant of CDK8 and CDK19, W105M, that maintained catalytic activity 
but specifically conferred resistance to CA (Fig. 2e,f, Extended Data Figs. 5a-f). Notably, 
CDK8 and CDK19 are the only mammalian CDKs with Trp (or any aromatic amino acid) at 
residue 105 (Extended Data Fig. 5g), underscoring the importance of the putative cation-π 
interaction.
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Next, we used CA to investigate whether Mediator kinase activity regulates SE-associated 
gene expression in AML cells. Global gene expression profiling in MOLM-14 cells treated 
with CA revealed that genes upregulated by CA at 3 hours were highly enriched for 
association with SEs by gene set enrichment analysis (GSEA)19 (Fig. 3a,b, Extended Data 
Fig. 6a, Supplementary Table 3). These SE-associated gene sets ranked among the most 
significantly enriched compared to all other signatures tested (Fig. 3c). Genes upregulated 
(≥1.2-fold) by CA were disproportionately associated with SEs in MOLM-14 cells (49/251, 
20%) compared to regular enhancers (173/5034, 3%) (Extended Data Fig. 6b, Fisher's exact 
test, p < 2.2 × 10−16). In contrast, of 102 genes downregulated (≥ 1.2-fold) by CA, only 
three were identified as SE-associated (3/251, 1%). Additionally, the association between 
CA upregulated genes (≥1.2-fold) and SE-associated genes correlated with CDK8 
occupancy (Fisher's exact test, p = 2.5 × 10−8), consistent with the notion that SEs are direct 
targets of CA treatment in MOLM-14 cells (Extended Data Fig. 6b).
Because SE-associated genes are more highly expressed compared to regular enhancer-
associated genes, we determined whether genes upregulated by CA had elongating RNA pol 
II and reduced traveling ratios (TR20, ratio of RNA pol II ChIP-seq reads in the proximal 
promoter versus the gene body). Indeed, CA upregulated genes exhibited reduced baseline 
TR (2.40-fold, p < 2.2 × 10−16, red vs. black curve, Fig. 3d, Extended Data Fig. 6c,d), 
consistent with CA upregulating active genes, including those associated with SEs. CA 
treatment further reduced the TR of these “CA upregulated” genes to a level similar to all 
SE-associated genes (yellow curve), in agreement with their increased expression after CA 
treatment (1.48-fold, p = 7.6 × 10−4, blue vs. red curve, Fig. 3d). Genes downregulated by 
CA experienced insignificant changes in TR (Extended Data Fig. 6e). Global effects of CA 
on RNA pol II TR, RNA pol II CTD phosphorylation, mRNA and total RNA levels were 
modest or negligible (Extended Data Fig. 6f-h).
We then examined whether upregulation of SE-associated genes might contribute to the 
antiproliferative activity of CA. SE-associated genes upregulated by CA were enriched in 
lineage-controlling master TFs identified in related CD14+ monocytes1, including tumour 
suppressors IRF1, IRF8, CEBPA, and ETV6 (Fig. 3e, Extended Data Fig. 7a-c). Increased 
expression of these genes individually, as well as SE-associated genes FOSL2 and 
CDKN1B, inhibited the proliferation of MOLM-14 cells (Fig. 3f, Extended Data Fig. 7d,e). 
ChIP-seq data revealed CDK8 occupancy at each gene's nearby SE (CEBPA, Fig. 1c; and 
ETV6 and FOSL2, Extended Data Fig. 7f). Furthermore, expression of CA-resistant CDK8 
W105M prevented upregulation of SE-associated genes by CA (Extended Data Fig. 7g). 
Therefore, upregulation of SE-associated genes, through Mediator kinase inhibition, could 
contribute to the antiproliferative activity of CA.
Growth of several AML cell lines was sensitive to CA and the BRD4 inhibitor I-BET151 
(Extended Data Table 1). The opposing effects of these inhibitors on SE-associated gene 
expression (Fig. 3b, red ticks are SE-associated genes, Fig. 3e, Extended Data Fig. 7c), 
however, suggest that AML cells might depend on a precise “dosage” of SE-associated gene 
expression. Indeed, MOLM-14 cell growth was inhibited by either reduced or increased 
expression of the same SE-associated genes, many of which were upregulated by CA and 
downregulated by I-BET151 (Fig. 3e,f and Extended Data Fig. 7c-e,h). Despite having 
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opposing effects on SE-associated genes, CA and I-BET151 co-treatment did not normalize 
transcription of these genes. Instead, I-BET151-induced transcriptional effects dominated, 
suggesting a dependence on BRD4 for CA-induced transcription (Fig. 3e and Extended Data 
Fig. 7c). Consistent with this, I-BET151 caused reduced occupancy of BRD4 and CDK8 on 
enhancer regions, and CA and I-BET151 co-treatment inhibited MOLM-14 cell growth 
(Extended Data Fig. 7i,j).
We extended our gene expression, ChIP-seq, and SE analysis to additional cell lines that 
were sensitive (SET-2 and MV4;11) and insensitive (HCT116 and K562) to CA and found 
that only the sensitive cell lines showed statistically significant enrichment of SE-associated 
genes among those upregulated by CA (Fig. 3g). These results support upregulation of SE-
associated genes as contributing to the antiproliferative effects of CA. However, we cannot 
exclude the contribution of other factors.
Finally, we assessed CA's in vivo antileukaemic activity. We first determined that CA had 
acceptable pharmacokinetic properties in mice for once-daily intraperitoneal (IP) dosing 
(Extended Data Fig. 8a) and then measured its efficacy in a disseminated human AML 
model21. CA afforded a dose-dependent reduction in disease progression (p < 0.0001), 
spleen weight, leukaemia cell burden, and survival (29.5-day median extension in survival, p 
< 0.0001, Fig. 4a,b and Extended Data Fig. 8b-e). Efficacious dosing was well-tolerated, 
with no loss in body weight or deleterious effects in peripheral blood of leukaemia-bearing 
or healthy, immunocompetent (CD-1) mice (Extended Fig. 8f,g,j-l). In a second AML model 
using SET-2 cells, CA afforded a 71% tumour volume reduction, also with no loss in body 
weight (Fig. 4c, Extended Data Fig. 8h). We confirmed that CA inhibited CDK8 in vivo by 
observing a dose-dependent reduction in STAT1 S727 phosphorylation in NK cells, which 
have CDK8-dependent constitutively phosphorylated STAT1 S727 (Fig. 4d, Extended Data 
Fig. 8i)22.
Although SE-associated genes are expressed at high levels, our results with CA show that a 
subset is restrained from even higher expression by Mediator kinase activity. CA's 
specificity, potency, favourable pharmacokinetics and long residence time make it a useful 
in vitro and in vivo probe of Mediator kinases and a promising lead for development of 
therapeutics.
Methods
Cell Culture
All media was supplemented with 100 U/mL penicillin and 100 μg/mL streptomycin. Cell 
line media: MV4;11, RS4;11, K562, HEL, MOLM-14, MEG-01 in RPMI-1640, 10% FBS; 
SET-2 in RPMI-1640, 20% FBS; UKE-1 in RPMI-1640, 10% FBS, 10% horse serum and 1 
μM hydrocortisone; SKNO-1 and TF-1 in RPMI-1640, 10% FBS, and 10 or 2 ng/mL GM-
CSF, respectively; HaCaT in DMEM, 10% FBS; and HCT116 in McCoy's 5A, 10% FBS 
(proliferation assay) or DMEM, 10% FBS (gene expression study). Sources: HepG2, 
MV4;11, RS4;11, MEG-01, TF-1, HCT116 and K562 from ATCC; SKNO-1 from DSMZ; 
HEL, UKE-1 and SET-2 from Ross Levine; and HaCaT, MV4;11-mCLP, and MOLM-14 
from Van Wilson, Andrew Kung, and Scott Armstrong, respectively. MOLM-14 cells were 
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authenticated by STR profiling and flow cytometry. All cell lines were routinely tested for 
mycoplasma.
Reagents
Compounds were stored under argon at –80 °C in 100% DMSO. Vehicle represents 0.1% 
DMSO unless otherwise specified. Sources: IFN-γ (PHC4031, Life Technologies), TGF-β1 
(R&D Systems), paclitaxel (LC Laboratories), I-BET151 (Tocris), PMA (Calbiochem), and 
doxorubicin and puromycin (Sigma-Aldrich). Immunoblot antibodies: anti-FLAG (F1804), 
anti-Actin (A5060) and anti-CDK19 (HPA007053) from Sigma-Aldrich; anti-Smad2/3 
(8685), anti-Smad2 pTail (3108), anti-STAT1 (9172), anti-phospho-STAT1 Tyr701 (9170) 
and anti-phospho-STAT1 Ser727 (9177), anti-CEBPA (2843), anti-ROCK1 (4035), anti-
ROCK2 (9029), anti-CDK8 (4101), anti-caspase-3 (9662) anti-PARP (9532) and anti-CDK9 
(2316) from Cell Signaling Technology (CST); anti-phospho-Smad2/3 T220/T179 
(600-401-C48) from Rockland; anti-CDK12 (NB100-87012) and anti-CDK13 
(NB100-68268) from Novus; and anti-CDK8 (A302-501A) and anti-Haspin (A302-241A) 
from Bethyl. ChIP antibodies: RNA pol II (Rpb1 N terminus, sc-899X lot B2713) from 
Santa Cruz; MED1 (A300-793A lot A300-793A-2), BRD4 (A301-985A lot 
A301-985A50-3), and CDK8 (A302-500A lot A302-500A-1) from Bethyl; and H3K4me3 
(ab8580 lot 1308511), H3K27Ac (ab4729 lot GR104852-1), and H3K4me1 (ab8895 lot 
GR61306-1) from Abcam.
Kinase Assays
Data was quantified with ImageJ and plotted and fitted with GraphPad Prism 6.0. For 
STAT1 transactivation domain (TAD), 750 ng of GST-STAT1 TAD (residues 639-750) was 
incubated with ~50 ng recombinant CDK8 module at 30 °C for 8 min in kinase buffer (25 
mM Tris pH 8, 2 mM DTT, 100 μM cold ATP, 100 mM KCl, 10 mM MgCl2 and 2.5 μCi 
[γ-32P] ATP (Perkin Elmer) per reaction). The assay included 2.5% DMSO, which did not 
inhibit kinase activity. 12% SDS-PAGE gels were subsequently silver stained, exposed for 
18 h on a Phosphor Screen and imaged (Typhoon 9400, GE Life Sciences). For pol II CTD, 
400 ng of GST-CTD (murine sequence) was incubated with ~40 ng recombinant CDK8 
module, 25 ng TFIIH, or 40 ng P-TEFb at 30°C for 60 min in kinase buffer. Kinase amounts 
were chosen to give similar total pol II CTD signal. 9% SDS-PAGE gels were silver stained 
and exposed as above. In vitro FLAG-CDK8 kinase assays used ~40 ng kinase and 500 ng 
GST-CTD. CDK12(714-1063):CycK(1-267) and CDK13(694-1039):CycK (1-267) were 
expressed in insect cells and used at ~500 nM per reaction. These regions of CDK12/13 
encompass the kinase domains (including the C-terminal extension helix) and the cyclin 
boxes, and are fully phosphorylated in the T-loop. For STAT1 or Smad2/3, cells were 
treated with compound for 1 h followed by IFN-γ or TGF-β1 for 1 h, then washed twice with 
cold PBS, and lysed (RIPA buffer with inhibitors R0278, P8340, P0044, P5762 Sigma-
Aldrich). Standard immunoblotting followed. All experiments were performed twice.
Protein purification
Buffers for purification and elution of recombinant proteins included 0.25 mM PMSF, 1 mM 
DTT, 1 mM benzamidine, and 1 mM sodium metabisulfite. TFIIH was captured from HeLa 
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nuclear extract using a monoclonal antibody for the p89 subunit immobilized to Protein A 
Sepharose (GE). Final purification of peptide-eluted TFIIH was performed on a 1 mL 
HiTrap Heparin HP (GE) resulting in 0.1-0.2 μM TFIIH. P-TEFb was purified as 
described 23 with a Superdex 200 polishing resulting in ~0.5 μM P-TEFb.Recombinant 
CDK8 module was purified as described24 with omission of the glycerol gradient.STAT1 
TAD and pol II CTD were expressed as N-terminal GST fusion proteins in E. coli BL21-
CodonPlus cells to OD600 0.5, then induced with 0.5 mM IPTG for 4 h at 30 °C and batch 
affinity purified with Glutathione Sepharose 4B (GE). Cells were lysed in H/E buffer (50 
mM Tris pH 7.9, 0.5 M NaCl, 0.5 mM EDTA, 10% glycerol, 0.5% NP-40), immobilized on 
Glutathione Sepharose 4B in H/E buffer for 3 h at 4 °C, washed with ~100 column volumes 
(CV's) of High Salt Buffer (50 mM Tris pH 7.9, 1 M NaCl, 0.5 mM EDTA, 0.5% NP-40, 8 
mM CHAPS), 0.5 M HEGN (20 mM HEPES pH 7.6, 0.5 M KCl, 0.1 mM EDTA, 10% 
glycerol, 0.02% NP-40) and 0.15M HEGN (20 mM HEPES pH 7.6, 0.15 M KCl, 0.1 mM 
EDTA, 10% glycerol, 0.02% NP-40). Fusion proteins were eluted in 2 × CV's of 30 mM 
reduced L-glutathione in GSH elution buffer (80 mM Tris pH 7.9, 0.15 M KCl, 0.1 mM 
EDTA, 10% glycerol, 0.02% NP-40). The GST-pol II-CTD was further purified by 
Superdex 200 polishing. FLAG-CDK8 WT and W105M mutants were expressed in 
MOLM-14 cells, captured using anti-FLAG M2 affinity resin (Sigma-Aldrich), and eluted 
with 1 mg/mL FLAG peptide in 0.15 M HEGN in 1 × CV twice. FLAG peptide elutions 
were stained with SYPRO Ruby to standardize kinase amounts. Purifications contained 
Cyclin C but not MED12 or MED13 (data not shown).
Native Kinase Capture Immunoblot and Native Kinome-wide Profiling
Experiments were performed as previously described15,25. 5 × 108 MOLM-14 cells were 
washed twice with 10 mL cold PBS and resuspended in 1 mL cold kinase buffer (20 mM 
HEPES pH 7.4, 150 mM NaCl, 0.5% Triton X-100, with inhibitors 11697498001, Roche 
and P5726, Sigma). Cells were lysed by sonication (2 × 10 s pulses with a 30 s break) and 
centrifuged (16,000 × g, 10 min). The supernatant was desalted through a column 
(732-2010, Biorad) and the eluted lysate was diluted to 5 mg/ml with kinase buffer. For each 
treatment, 475 μL of the lysate was pre-incubated with 10 μL MnCl2 (1 M) and 5 μL 
compound to the desired concentration at room temperature for 30 min. Uninhibited kinases 
were captured with 10 μL ActivX desthiobiotin-ATP probe (0.25 mM; 88311, Pierce) at 
room temperature for 10 min. Samples were mixed with 500 μL urea (8 M; 818710, 
Millipore) and 50 μL streptavidin agarose (20359, Thermo) for 60 min at room temperature 
on a nutator. Beads were washed twice with a 1:1 mixture of kinase buffer and 8 M urea, 
and collected by centrifugation (1,000 × g, 1 min). Proteins were eluted from the beads with 
100 μL 2× LDS sample buffer (NP0007, Life) at 95 °C for 10 min. Samples were analysed 
by standard immunoblotting and HRP detection. Experiment was performed twice. Native 
kinome profiling was performed with MOLM-14 cell lysate according to the KiNativ 
Method by ActivX Biosciences. For each peptide quantitated, the change in MS signal for 
the treated samples relative the MS signal for the control samples was expressed as 
percentage inhibition. The results correspond to one experiment of duplicates for each CA 
concentration. The percentage changes in MS signal reported are statistically significant 
(Student T-test score <0.04).
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Recombinant Kinome-wide Selectivity Profiling and IC50 determination
A radiometric protein kinase assay was used (PanQinase activity assay; performed by 
ProQinase GmbH) as described26. IC50 determination for CDK8/CCNC (8.3 nM with 1.0 
μM ATP and 1.0 μg/50uL of substrate RBER-IRStide) was performed as duplicate 
measurements and IC50 was calculated using Prism 5.04 with sigmoidal response, top fixed 
at 100% and bottom at 0% with least-squares fitting.
Binding and Kinetics
Measurements listed were made using the Proteros reporter displacement assay as 
previously described27. 0.62 nM CDK8/CCNC was preincubated with a reporter probe at a 
concentration equal to its binding affinity (Kd) in 20 mM MOPS [pH 7.0], 1 mM DTT, and 
0.01% Tween20 (final reaction volume 10 μl in black polypropylene U bottom plates, 
Corning 4514). After transfer of serially diluted CA, probe displacement was monitored for 
60 min. Kd values were calculated using the Cheng-Prusoff equation from the IC50 values 
obtained from the percentage displacement values at the last time point measured. 
Association rate constant was calculated from the decay rate of probe displacement. 
Dissociation rate constant was determined as the product of Kd × association rate constant. 
Residence time was calculated as 1/koff. Error was determined by Gaussian error 
propagation from the IC50 error. Experiment was performed once.
Crystallization, Data Collection, and Refinement
Human CDK8/CCNC were expressed and purified as previously described27. Co-crystals at 
a protein concentration of 11.3 mg/ml with 1 mM CA were obtained in 20% PEG 3350 and 
0.20 M sodium formate at 20° C and shock-frozen with 25% ethylene glycol as 
cryoprotectant. Diffraction data were collected at the SWISS LIGHT SOURCE (SLS, 
Villigen, Switzerland), beamline X06SA with a wavelength of 1.00004 Å at 100 K, and 
processed using XDS and XSCALE28. The structure was solved by molecular 
replacement 29, subsequent model building and refinement (including TLS refinement) was 
performed with COOT30 and CCP431,32. The Rfree validation was based on a subset of about 
3.4% of the reflections omitted during refinement. Waters were included at stereochemically 
reasonable sites. Final refinement cycles led to a model with Rwork value 21.7% and Rfree 
value 26.6%. All main-chain angles of non-glycine residues fall into the conformationally 
most favoured (93.2%), additionally allowed (6.6%) or generously allowed (0.2%) regions 
of the Ramachandran plot. Graphical figures were prepared using PyMOL33. Values in 
parenthesis in Extended Data Table 2 refer to the highest resolution-shell.
Cell Growth Assay
All suspension cells were plated (96-well) in triplicate at 5,000 to 30,000 cells/well for 
testing (n = 3). Viable cell number was estimated after 3, 7, and 10 days by counting viable 
cells from one vehicle well, generating a cell dilution series, transferring 20 μL/well in 
duplicate to a 384-well plate, and performing a linear regression to CellTiter-Glo (Promega) 
response (SPECTRAmax M3, Molecular Devices). Cells from all wells were also 4-fold 
diluted in media and transferred in duplicate for CellTiter-Glo measurement. On days 3 and 
7, an equal volume for all wells were split-back with fresh media and compound, such that 
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the resulting cell density for the vehicle well matched the initial seeding density. For days 7 
and 10, estimated cell number represents the split-adjusted theoretical cell number. HCT116 
were plated (96-well) in triplicate at 250 cells/well. Cells were incubated in the presence of 
vehicle, 1 μM paclitaxel, or compound. On day 7, CellTiter-Blue (Promega) response was 
measured and values were normalized to vehicle (100% growth) and paclitaxel (0% growth). 
For growth assays with inhibitors, n=3 for each concentration with two independent 
experiments, averaged for Extended Data Table 1, and one experiment shown for graphs of 
percent growth vs. concentration and time, Fig. 2e and Extended Data Fig. 4a.
Flow Cytometric Analysis
Cells were plated (6-well) in triplicate at 150,000 cells/mL for 1-day, 2-day, and 3-day 
timepoints. For the 6-day timepoint, cells were plated at 35,000 cells/mL and diluted to 
150,000 cells/mL with media and compound on day 4. For cell cycle, cells were washed 
twice with PBS, fixed with 70% ethanol at 4 °C overnight, washed with PBS, and stained 
with 50 μg/mL propidium iodide (eBioscience) for 1 h at 37°C. For apoptosis, cells were 
stained using Annexin V-FITC (BD Pharmingen) and 7-AAD (Miltenyi Biotec). Samples 
were acquired on a BD LSR II and analysed using FlowJo v7.6.5. For the SET-2 
differentiation assay, cells were cultured in triplicate with either 50 nM CA, 50 ng/mL PMA 
(positive control), or vehicle for three days. Cell pellets were collected at 4°C, washed three 
times with cold PBS, and stained with anti-CD61-PE (ab91128) or anti-CD41-PerCP 
(ab134373). For each experiment, n=3 biological replicates with two independent 
experiments and one shown.
Plasmids, Mutagenesis, Packaging, Transduction, Selection, and siRNA
5'-FLAG-tagged CDK8 and CDK19 were cloned from pBabe.puro.CDK8.flag34 (Addgene 
19758) and F-CDK8L (Addgene 24762) into pLVX-EF1alpha-IRES-mCherry and pLVX-
EF1alpha-IRES-ZsGreen (Clontech) and transformed into E. coli (One Shot Stbl3, 
Invitrogen). Point mutations were introduced by whole plasmid PCR (QuikChange II XL 
Site-Directed Mutagenesis Kit, Agilent). pLVX lentiviral vectors were co-transfected with 
psPASx and pMD2.G (Addgene) in 293T cells. After 48 h, viral supernatants were collected 
and passed through a 0.45 μm filter (Millipore). For transductions, 24-well plates were 
coated with 500 μL of 20 μg/ml RetroNectin (Clontech) at 4°C overnight, blocked with 2% 
BSA for 30 minutes, washed with PBS, and 300-500 μL of viral supernatant was added. The 
plates were centrifuged (2000 × g, 1.5 h) and then set in an incubator. After 2 h, viral 
supernatant was removed and 500 μL/well of 200,000 cells/mL was added. After 1-3 days, 
the cells were expanded and isolated by FACS. FLAG-CEBPA (gift from Jarrod Marto), 
FLAG-IRF1 (PlasmID, HMS, HsCD00045286), FLAG-IRF8 (PlasmID HMS, 
HsCD00438293), ETV6-Myc-FLAG (Origene, SC118922), CDKN1b-Myc-FLAG 
(Origene, SC117607), and FOSL2-Myc-FLAG (Origene, SC110898) were cloned into the 
Tet-On inducible system pLVX-TRE3G-mCherry or pLVX-TRE3G-ZsGreen (Clontech), 
transformed into E. coli (Stellar Competent Cells, Clontech), packaged into lentiviral vectors 
and cotransduced with regulator vector pLVX-EF1a-Tet3G. After one week of selection 
with puromycin (1 μg/ml) and G418 (400 μg/ml), cells were plated in the presence of 100 
ng/mL doxycycline to assess 7-day growth via Cell-Titer Glo. SiRNA against CEBPA 
(Ambion s2888), IRF1 (Ambion s7501), ETV6 (Ambion s4867 and s4866), FOSL2 (Ambion 
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s5345), and IRF8 (Ambion s7098) or scrambled control (Ambion 4390843) were introduced 
into cells by electroporation (Amaxa Nucleofector II, Program T-019). After 24 hours, cells 
were plated to assess 3 or 4-day growth via Cell-Titer Glo. Knockdown efficiency was 
assessed after 24 hours by immunoblot or after 48 hours by ddPCR. Results shown in Fig. 
3g represent a single transduction or a single electroporation. SiRNA electroporation and 
inducible expression cell growth assays were performed 2-6 times. For ETV6, two siRNAs 
were tested with data for siRNA s4867 shown in figures.
Gene Expression, Gene Ontology and GSEA
Leukaemia cells were plated (12-well) in triplicate at 500,000 to 800,000 cells/mL and 
incubated in the presence of vehicle or CA (25 nM 3 h for K562, MOLM-14 and MV4;11; 
10 nM 24 h for MOLM-14; 25 nM 4 h for SET-2, n=3 for each cell line). Cells were then 
washed twice with cold PBS, and snap frozen. RNA was isolated (RNeasy Plus Microkit, 
Qiagen or TRIzol, Life Technologies), processed, and, for K562, MOLM-14, and MV4;11, 
hybridized to the Human U133 Plus 2.0 microarray (Affymetrix). Microarrays were 
processed with Bioconductor packages affyQCReport 35 for quality control and affy for 
background correction, summarization, and normalization using rma36. Probe sets present in 
at least 1 sample (based on affy mas5call) and for which the interquartile range was 
>log2(1.2) were retained for further analysis. The limma Bioconductor package37 was used 
for differential expression (DE) analysis of CA-treated vs DMSO control samples 
(Benjamini-Hochberg38 adjusted p-value <0.05). SET-2 and HCT116 gene expression was 
measured by RNA-seq. SET-2 RNA-seq libraries were prepared and processed using the Ion 
Torrent workflow. Reads were aligned in two passes, first with rnaStar 39 (v.2.3.0e) then 
with BWA40 (v.0.7.5a) for remaining unmapped reads, both using default parameters. 
Mapped reads were merged and counted using HTSeq41 (v.0.5.3p3) with -s yes -m 
intersection-strict. The Bioconductor package DESeq42 was used for DE analysis (FDR < 
0.05 and 2-fold change) and normalization. HCT116 cells were grown to approximately 
80% confluence and were treated with either 100 nM CA or DMSO for 3 h (n=3). Cells 
were then washed twice with cold PBS and scraped into TRIzol reagent (Life Technologies). 
After harvesting the RNA, it was further purified using an RNeasy mini kit (Qiagen) with an 
on-column DNase I digestion. Libraries for Illumina sequencing were generated via the 
Illumina TruSEQ stranded mRNA prep kit. Samples were run in a single lane on an Illumina 
HiSEQ 2000 sequencer with a single read flow cell using 1x 50bp reads and a 6-cycle index 
read. Reads were mapped to the hg19 reference genome using Tophat2 v. 2.0.6 with custom 
settings including the setting of –-library-type fr-firstrand to appropriately account for the 
stranded nature of the protocol. HTSeq v. 0.6.1 was used to obtain read counts over 
annotated genes and differentially expressed genes were called by DESeq v. 1.10.1 with a 
padj value of less than 0.01. Counts were normalized for GSEA using the limma voom 
function 43. Expression data for the I-BET151 comparison were downloaded from 
ArrayExpress (https://www.ebi.ac.uk/arrayexpress/, accession:E-MTAB-774) and processed 
files used as is. Gene lists were submitted to the DAVID web server (http://
david.abcc.ncifcrf.gov) for functional annotation44. GSEA version 2.0919 was carried out 
using signal-to-noise on natural values as the metric. Signatures included curated gene sets 
(C2, v.3) downloaded from the Broad's MSigDB as well as signatures curated from in-house 
and published data sets.
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ChIP-seq
Untreated cells or cells treated with CA (25 nM, 6 h), iBET-151 (500 nM, 6 h) or vehicle 
were crosslinked for 10 min at room temperature by addition of one-tenth of the volume of 
formaldehyde solution (11% formaldehyde, 50 mM HEPES pH 7.4, 100 mM NaCl, 1 mM 
EDTA, 0.5 mM EGTA) to the media followed by 5 min quenching with 125 mM glycine. 
For CDK8 and MED1 ChIPs, cells were instead centrifuged, resuspended in serum-free 
media, and crosslinked at room temperature by addition of an equal volume of 2% 
formaldehyde in serum-free media for 10 min followed by quenching with 125 mM glycine 
for 5 min. Cells were then washed twice with cold PBS and snap frozen. ChIP was 
performed essentially as previously described2. Briefly, cells were lysed with lysis buffer 1 
(50 mM HEPES pH 7.4, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, and 25% 
Triton X-100) and washed with lysis buffer 2 (10 mM Tris-HCl pH 8.0, 200 mM NaCl, 1 
mM EDTA, and 0.5 mM EGTA). For H3K4me3, H3K27me3, H3K27Ac, H3K4me1, and 
pol II, the nuclei were resuspended in 10 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM EDTA 
pH 8.0, 0.5 mM EGTA, 0.1% Na-deoxycholate, and 0.2% SDS, sheared for 2 min (Branson 
S220D sonifier, pulse, 0.7 s on, 1.3 s off, 12-14 watts) on wet ice, and then Triton X-100 
was added to 1% v/v. For MED1 and CDK8, the nuclei were resuspended in 50 mM Tris-
HCl pH 7.5, 140 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.1% SDS, and 1% Triton X-100 
then sheared for 4 min (pulse, 0.7 s on, 1.3 s off, 10-12 watts) on wet ice. Sonicated lysates 
were cleared and incubated overnight at 4 °C with Protein G magnetic Dynal beads (50 μL) 
pre-bound with the indicated antibodies (5 μg). Beads were washed with sonication buffer, 
sonication buffer with 500 mM NaCl, LiCl wash buffer (20 mM Tris-HCl pH 8.0, 1 mM 
EDTA, 250 mM LiCl, 0.5% NP-40, 0.5% sodium deoxycholate,) and TE. Bound complexes 
were eluted with 50 mM Tris-HCl pH 8.0, 10 mM EDTA, 1% SDS at 65 °C and reverse 
crosslinked at 65°C. RNA and protein were digested using RNAse A and proteinase K, 
respectively, and DNA was purified using Qiagen MinElute columns. Libraries for Illumina 
sequencing were prepared using the Illumina TruSeq ChIP Sample Preparation kit with the 
following exceptions. After end-repair and A-tailing, ChIP DNA or whole cell extract DNA 
was ligated to Illumina RNA adaptors with unique indices. Alternatively, libraries were 
prepared using the KAPA Hyper Prep Kit for Illumina and ligated to unique Bioo Scientific 
NEXTflex barcode adaptors. Following ligation, libraries were amplified with 16-18 cycles 
of PCR and were then size-selected using a 2% gel cassette in the Pippin Prep System from 
Sage Science. For histone modifications and RNA pol II, DNA fragments of size 200-500bp 
were captured. For CDK8 and MED1, DNA fragments of size 200-450bp were captured. 
Libraries were quantified by qPCR utilizing the KAPA Biosystems Illumina Library 
Quantification kit. Libraries with distinct indexes were then combined in equimolar ratios 
and run together in a lane on the Illumina HiSeq 2500 for 40 bases in single read mode.
ChIP-seq Data Analysis
ChIP-seq data sets were aligned using Bowtie (v0.12.8)45 to build version NCBI37/HG19 of 
the human genome (-n 1 -m 1 --best --strata). Duplicate reads were removed using Picard 
tools (version 1.88). For CDK8, peaks were called with both SPP46 and MACS version 
1.447 using default significance cut-off values. SPP cross-correlation analysis was used for 
both quality control48 and to set the strand shift parameter for MACS. Regions of interest 
identified by both peak callers were retained and merged. Regions overlapping >70% with 
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RepeatMasker regions (downloaded Nov. 16, 2012 from UCSC) were excluded from further 
analysis. Retained regions were annotated by overlap with RefSeq genes (genomic 
coordinates downloaded from UCSC refgene table Apr. 26, 2013) using bedtools49. 
Retained regions were assigned to one of the following categories: (1) promoter = 
TSS-500bp to TSS+200bp, (2) body = TSS+201bp to TES, (3) proximal enhancer = 
TSS-5kb to TSS-501bp, and (4) 3' UTR = TES+1bp to TES+5kb. All other regions were 
termed “desert” hits. Any gene satisfying the overlap criteria was included in the 
corresponding category. Traveling ratios were calculated essentially as described50. Briefly, 
mapped read coordinates were first extended 3' to 200 bases to capture the full fragment 
coverage. The RefSeq coordinates used for annotation were then used to count extended pol 
II reads falling in the range of TSS-30bp to TSS+300bp and those falling in the remainder of 
the gene body (TSS+301 to TES). Very short transcripts (<630bp) were excluded, as were 
cases with very low counts in both regions. Input reads were subtracted and counts were 
scaled to reads per kilobase. Transcripts sharing identical TSS and TES coordinates were 
represented a single time in the count statistics. ChIP-seq tracks were smoothed by 
calculating the density per million mapped reads in 300bp bins at 50bp intervals and were 
visualized using Integrative Genomics Viewer. ChIP-seq density maps were generated using 
ngsplot (v2.08)51. Heatmap of semi-supervised clustering in Fig. 1a of total signal on CDK8 
positive regions was carried out as follows: (1) peaks were individually identified for each 
of the 6 ChIPs using MACS2 at default p-value cutoff; (2) all peaks were combined and 
merged into non-redundant regions using mergeBed (-d 0); (3) within each unique region, 
ChIP reads were counted and matched input reads were subtracted after scaling each to 
million mapped reads; (4) clusters were grouped by ChIPs represented in a given region into 
64 categories in the following order : H3K4me1, H3K27ac, Pol II, MED1, and BRD4; (5) 
each group was ordered by decreasing CDK8 signal per region; and (6) ChIP samples were 
clustered by Euclidean distance of ChIP signal per region after median centring and 
normalization. A similar approach was used for BRD4 and CDK8 ChIPs in MOLM-14 cells 
treated with DMSO or I-BET151. In this case, non-promoter-associated regions in which I-
BET151 treatment reduced BRD4 signal > 2-fold were ordered by log2 fold-change.
Irreproducibility Discovery Rate (IDR) Analysis
Reproducibility of two independent H3K27Ac ChIP-seq experiments carried out in cells 
treated with either DMSO or CA for 3hrs was assessed according to the pipeline developed 
for the ENCODE project (https://sites.google.com/site/anshulkundaje/projects/idr) 52. IDR 
was determined as recommended on peaks called by SPP46 at FDR < 0.5. At this threshold, 
SPP reported between 180,000 and 300,000 peaks, depending on the exact combination of 
sample and input, most of which are expected to be noise. Under both treatment conditions, 
the number of high-confidence peaks (IDR threshold < 0.01 for true replicates and pseudo-
replicate self-consistency tests and < 0.0025 for pseudo-replicate pooled-consistency 
analysis) identified based on signal value in the replicates and pseudo-replicates was within 
the recommended 2-fold range, indicating good reproducibility. The number of peaks with 
IDR < 0.01 in the true replicates was used to make the final selection of distinct, non-chrM 
pooled replicate peaks. Regions within 200nt of each other were merged to generate the final 
peaks list. The same approach was used to determine reproducible peaks in two independent 
BRD4 and CDK8 ChIP experiments in MOLM-14 cells treated with DMSO or I-BET151.
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Identification of SEs
MED1 signal was measured in active enhancers (i.e., regions enriched in both H3K4me1 
and H3K27ac) after extending MED1 ChIP-seq reads 100 bases in a strand-aware fashion. 
Enhancer regions were sorted based on their MED1 signal and the inflection point of the 
curve determined. Enhancers with MED1 signal above the inflection point were retained as 
SEs2. In a separate approach, using only the MED1 ChIP-seq data and the ROSE software 
from the Young laboratory1, we found > 80% agreement with our K4me1+/K27ac+ MED1 
SEs. ROSE was used thereafter to identify SEs using BRD4, H3K27ac (± CA, 3 h), and 
CDK8 ChIP-seq on peaks called by MACS 1.4. For K562 and HCT116, H3K27ac ChIP 
samples and their matched inputs were downloaded from the ENCODE project repository at 
UCSC (sample identifiers and references in Supplementary Table 1). For HCT116, CDK8 
ChIP-seq data and matched input was downloaded from GSE3825853. SE-associated genes 
were assigned to the nearest expressed transcript, based on H3K27ac signal in a 500nt 
window centered on the TSS1. For Extended Data Fig. 1e, we normalized each experiment's 
signal (after adjusting to million mapped reads and subtracting input signal) to show values 
from independent ChIP-seq experiments on a common scale. Normalized signal for each 
enhancer, x, is thus (x - minimum)/(maximum - minimum). Each ChIP-seq experiment 
yielded different numbers of enhancer regions so we mapped each experiment's enhancer 
ranks to [0,1] by calculating (rank-1)/(maximum rank - 1).
RNA Levels, Digital Droplet PCR (ddPCR), and qRT-PCR
Total RNA was isolated from 500,000 MOLM-14 cells (RNeasy Plus Mini Kit, Qiagen) and 
quantified by Nanodrop. mRNA was subsequently isolated (Dynabeads mRNA Purification 
Kit, Life Technologies) and quantified by Nanodrop. For ddPCR, total RNA was reverse-
transcribed into cDNA (High Capacity cDNA Reverse Transcriptase Kit, Applied 
Biosystems) and used (ddPCR Supermix for Probes, no dUTP, Bio-Rad 186-3024) with 
TaqMan FAM probes for genes of interest and ACTB (VIC) as the reference gene. Droplets 
were generated in the QX200 Droplet Generator, thermocycled, and read on the QX200 
Droplet Reader. Total RNA per cell was measured by isolating total RNA from 106 cells 
using the mirVana miRNA Isolation Kit (Life Technologies) and quantifying by Nanodrop. 
The difference in copy numbers of specific mRNAs before and after treatment (Fig 3e) was 
determined relative to copies of ACTB mRNA per cell. Probes used (Life Technologies): 
CEBPA (Hs00269972_s1), ETV6 (Hs00231101_m1), IRF1 (Hs00971960_m1), IRF8 
(Hs00175238_m1), RREB1 (Hs01002873_m1), CDKN1B (Hs01597588_m1), GFI1 
(Hs00382207_m1), JARID2 (Hs01004460_m1), BHLHE40 (Hs01041212_m1), and ACTB 
(4325788). qRT-PCR for checking siRNA knockdown was performed with iTaq Universal 
Probes Supermix (Bio-Rad), n=3, or by ddPCR.
In Vivo Studies
Studies were performed at Charles River Laboratories (CRL) and Dana Farber Cancer 
Institute (DFCI) where indicated and approved by Harvard University and each institution's 
respective animal care and use committee. For pharmacokinetic studies, serial blood samples 
from 7 week old male CD-1 mice (n=3 per timepoint) were collected (no blinding) into 
K2EDTA tubes, centrifuged, transferred into 96-well plates (matrix tubes), stored at –20 °C, 
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and analysed by HPLC/MS/MS (in-life performed at CRL). Study size was determined by 
the need for three blood samples per timepoint with three blood samples collected per 
mouse. The MV4;11 xenograft model were performed as previously described21 (in-life 
performed at DFCI) Two million MV4;11-mCLP cells were injected into the tail vein of 7-
week-old female NOD-SCID-IL2Rcγnull (NSG) mice (The Jackson Laboratory) and tumour 
burden was assessed by bioluminescence imaging (BLI) using an IVIS Spectrum system 
(Caliper Life Sciences). 7 days post injection, leukaemia establishment was documented by 
BLI and mice were assigned to groups to achieve a similar mean BLI and treated IP with 
vehicle (20% hydroxypropyl-β-cyclodextrin) or CA once daily for 15 days. After 30 days, 
blood counts were obtained (Hemavet 950 F, Drew Scientific) and spleen, femur, and 
peripheral blood cells were collected and analysed by flow cytometry (LSR Fortessa, BD 
Biosciences) from 3 mice/group. The mice and a portion of the spleen were preserved in 
bouins after body cavities were opened and visceral organs exposed. Samples from all 
organs were then dissected and placed in 9 cassettes/mouse. Tissues were paraffin 
embedded, sectioned at 6 microns and stained with haematoxylin and eosin. Survival was 
measured as the time from therapy initiation until moribund state. We selected 11 mice per 
group to match previous survival analysis in the model21 (n=8) and to have 3 additional 
mice per group for disease burden comparison. Blinding was only done for histopathology 
analysis. For the SET-2 xenograft model (in-life performed at CRL), 8 to 12 week old 
female SCID Beige mice (Charles River) were injected subcutaneously in the flank with 107 
SET-2 cells in 50% matrigel (0.2 mL/mouse). When tumours reached an average size of 
80-120 mm3, mice were assigned to groups to achieve a similar mean tumour size and 
treatment commenced without blinding. Tumour volumes were measured using calipers and 
calculated as (width2 × length)/2. Percent tumour growth inhibition was calculated as mean 
volumes of (vehicle-treatment)/(vehicle-initial)×100. We selected 10 mice per group to 
safeguard against the IACUC requirement to stop dosing a group if >10% mortality occurs. 
For safety testing (in-life performed at DFCI), 8 week old female CD-1 mice were treated 
once daily without blinding for 15 days and weighed daily. Two hours after the last dose, 
blood counts were obtained and blood chemistry was analysed. Three mice per group were 
selected as a minimum for comparison. For STAT1 pS727 inhibition, 6 to 10 week old 
female C57BL/6 mice were treated once daily for two days (in-life at CRL, not blinded). 
One hour after the second dose, NK cells were isolated by dissociation of spleenocytes from 
isolated spleens, lysis of erythrocytes, and isolation of DX5+ cells (MiniMACS CD49b, 
Miltenyi Biotec) and analyzed by immunoblot and densitometry (ImageJ, STAT1 pS727 
level normalized to beta-actin). We selected 3 mice per group as a minimum for comparison. 
Statistical analyses were performed using GraphPad Prism 6.0. For p-value determinations, 
two-way or one-way ANOVA was used with Dunnett's multiple comparison testing and p-
value adjustment. Dotted purple lines were from the Mouse Phenome Database (The 
Jackson Laboratory).
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Extended Data
Extended Data Figure 1. CDK8 ChIP-seq defines SE-associated genes
(a) The antibody used for CDK8 ChIP-seq (Bethyl A302-500A) was validated by IP-
western. IP was conducted with Bethyl A302-500A (2 μg) on MOLM-14 whole cell extract 
and Western blot (WB) was performed on split IP lysate or 5% input with either anti-CDK8 
Bethyl A302-501A (left panel), anti-CDK8 Bethyl A302-500A (right panel), or normal 
rabbit IgG (CST, 2729), experiment performed once. (b) MED1 and CDK8 density is highly 
correlated on active enhancer regions marked by H3K4me1 and H3K27ac (Corr = 0.86, R2 
= 0.84) in MOLM-14 cells. The pink box represents SEs. (c) Hierarchical clustering 
dendrogram of CDK8, MED1, BRD4, H3K27ac, RNA pol II, and H3K4me1 ChIP-seq 
signal. (d) Distribution of CDK8 signal with input subtracted across CDK8 bound regions. 
Regions to the right of inflection point are considered SEs. (e) Distribution of CDK8, 
MED1, BRD4, and H3K27ac signal across putative enhancer regions. Regions to the right 
of the distribution inflection point are considered SEs. (f) ChIP-seq profile plots centered 
around MED1-defined SE and regular enhancer regions. Flanking regions are 2.5kb.
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Extended Data Figure 2. CA inhibition of and binding to CDK8
(a) CA inhibition of CDK8 module phosphorylation of CDK8 and STAT1 S727 substrate 
(mean ± s.e.m., n=3 biological replicates, one of two experiments shown, autorad in 
Supplementary Figure 1). (b) CA inhibition in vitro of CDK8 module activity but not 
CDK12:Cyclin K or CDK13:Cyclin K activity up to 10 μM. Equal amounts (silver stain) of 
GST-CTD were used as the substrate in in vitro kinase assays. The amount of each kinase 
used was empirically determined to give approximately the same GST-CTD signal under the 
assay conditions. “ns” is no substrate (kinase only) and “GST-CTD-P” is phosphorylated 
GST-CTD. One of four experiments shown. (c) Immunoblot showing that CA selectively 
and dose-dependently inhibits capture of native CDK8 (IC50 ~10 nM) and CDK19 (IC50 ~ 
100 nM) from MOLM-14 lysates but did not inhibit capture of CDK9, CDK12, CDK13, 
ROCK1, ROCK2 or GSG2. One of two experiments shown, full scan in Supplementary 
Figure 1. (d) Immunoblots showing CA inhibition of CDK8-dependent IFN-γ-stimulated 
STAT1 S727 phosphorylation in MOLM-14 cells and CA inhibition of TGF-β-stimulated 
Smad2 T220 and Smad3 T179 phosphorylation in HaCaT cells (IC50 < 100 nM). One of two 
experiments shown, full scan in Supplementary Figure 1. (e) In vitro kinase activity 
profiling (mean for kinase reaction, n=2 biological replicates, experiment performed once). 
(f,g) CA dose-dependent inhibition of (f) CDK8/CCNC complex (IC50 = 5 nM) and (g) 
GSG2 (IC50 = 130 nM) as measured for the (e) (n=1, experiment performed once). (h) 
Dendrogram representation of results shown in Fig. 2c for 1 μM CA.
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Extended Data Fig. 3. CA/CDK8/CCNC ternary complex
(a) 2.4 Å crystal structure of the human CA/CDK8/CCNC ternary complex shown as a 
Corey-Pauling- Koltun (CPK) model. (b) CA and neighbouring protein side chains are 
shown as a stick model coloured according to the chemical atom type (CA in cyan, CDK8/
CCNC in grey, N in blue, O in red and S in yellow). CA is shown superimposed with the 
refined 2Fo -Fc electron density map contoured at 1.0 s. Hydrogen bonds are indicated as 
green dotted lines. (c) A portion of the CA-CDK8-CCNC crystal structure showing the CA 
binding pocket of CDK8 (with and without a semi-transparent surface; CA in gold, CDK8 in 
gray) with certain residues and CA in stick representation. Dotted red lines indicate H-
bonds. Key residues and binding elements are labelled.
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Extended Data Fig. 4. Antiproliferative activity of CA and I-BET151
(a) Plots showing antiproliferative activity of CA over time for selected sensitive cell lines 
and concentrations (mean ± s.e.m., n=3 biological replicates, one of two experiments 
shown). (b) Immunoblots showing that CA inhibits CDK8-dependent IFN-γ-stimulated 
STAT1 S727 phosphorylation equally well in cells sensitive or insensitive to the 
antiproliferative activity of CA (one of two experiments shown, full scan in Supplementary 
Figure 1). (c) Immunoblots showing CDK8 and CDK19 levels upon 24 h CA treatment in 
sensitive cell lines MV4;11 and MOLM-14 (one of two experiments shown, full scan in 
Supplementary Figure 1). (d) CD41 and CD61 (vehicle vs. CA, p= 0.04 and 0.005, 
respectively, two-tailed t-test) on SET-2 cells after 3 days of indicated treatment (mean ± 
s.e.m., n=3 biological replicates, one of two experiments shown). (e) DNA content and 
Annexin V staining of indicated cell lines upon treatment with CA (mean ± s.e.m., n=3 
biological replicates, one of two experiments shown). (f) Immunoblots of CA dose- and 
time-dependent induction of PARP and caspase-3 cleavage for indicated cell lines (one of 
two experiments shown, full scan in Supplementary Figure 1).
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Extended Data Figure 5. Mediator kinases mediate the antiproliferative activity of CA
(a) We evaluated point mutations to CDK8 residues lining the CA binding pocket: Ala155, 
His106, Asp103, and Trp105. Expression of CDK8 A155I, A155F, A155Q, H106K and 
D103E in MOLM-14 cells afforded only modest desensitization to CA. Differential 
sensitivity of MOLM-14 cells to CA upon expression of indicated mutant FLAG-CDK8 
proteins (mean ± s.e.m., n=3 biological replicates, experiment performed once). (b) 
Immunoblots showing that FLAG-CDK8 or FLAG-CDK19 and FLAG-CDK8 W105M or 
FLAG-CDK19 W105M are expressed at similar levels in MOLM-14, MV4;11, and 
SKNO-1 cells (experiment performed once, full scan in Supplementary Figure 1). (c) 
Differential sensitivity of MV4;11 and SKNO-1 cells to CA upon expression of FLAG-
CDK8, FLAG-CDK19, FLAG-CDK8 W105M and FLAG-CDK19 W105M, legend as in d 
(mean ± s.e.m., n=3 biological replicates, one of two experiments shown). (d) Control 
showing that expression of FLAG-CDK8 W105M or FLAG-CDK19 W105M in MOLM-14, 
MV4;11, and SKNO-1 cells does not confer resistance to antiproliferative agents paclitaxel 
and doxorubicin (mean ± s.e.m., n=3 biological replicates, one of two experiments shown). 
(e) Purified FLAG-CDK8 W105M and FLAG-CDK19 W105M remain catalytically active 
for phosphorylation of CTD in vitro but are resistant to inhibition by CA (mean ± s.e.m., 
n=3 biological replicates, experiment performed once). (f) Representative autorad and silver 
stain images supporting quantitation shown in (e). (g) Sequence alignment of human CDKs. 
Sequence alignment was performed on segments of CDK1-20 using Clustal Omega. The 
unique Trp105 residue in CDK8 and CDK19 is highlighted in red, and is absent from other 
CDKs (orange box). UniProt Knowledgebase entries: CDK1, P06493; CDK2, P24941; 
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CDK3, Q00526; CDK4, P11802; CDK5, Q00535; CDK6, Q00534; CDK7, P50613; CDK8, 
P49336; CDK9, P50750; CDK10, Q15131; CDK11A, Q9UQ88; CDK11B, P21127; 
CDK12, Q9NYV4; CDK13, Q14004; CDK14, O94921; CDK15, Q96Q40; CDK16, 
Q00536; CDK17, Q00537; CDK18, Q07002; CDK19, Q9BWU1; CDK20, Q8IZL9.
Extended Data Fig 6. CA disproportionately affects expression of SE genes in MOLM-14 cells
(a) GSEA plots showing positive enrichment of SE-associated genes (SE genes), defined by 
ChIP-seq signal for indicated factors, with 3 h CA treatment in MOLM-14 cells (differential 
expression vs. DMSO controls). (b) Venn diagram showing the overlap between SE genes 
and genes upregulated ≥1.2-fold upon 3 h CA treatment in MOLM-14 cells (“CA 
upregulated genes”). Numbers in red indicate the percentage of CDK8-occupied genes (peak 
within ±5kb of the gene). (c,d) RNA pol II ChIP-seq metagene profile plots of unchanged 
genes (black), SE-associated genes (SE genes, yellow), CA upregulated genes with vehicle 
treatment (no CA; red), and CA upregulated genes with 6 h CA treatment (with CA; blue). 
(e) Cumulative distribution plot of RNA pol II traveling ratio (TR) after treatment with CA 
(25 nM, 6 h) or vehicle across genes ≥1.2-fold downregulated by CA after 3 h (1.16-fold, p 
= 0.31, Kolmogorov-Smirnov test) and (f) across all genes (1.21-fold, p < 2.2 × 10−16, 
Kolmogorov-Smirnov test). (g) CA does not significantly change the total amount of RNA 
or mRNA in MOLM-14 or MV4;11 cells (mean ± s.e.m., n=3 biological replicates, 
experiment performed once) after treatment with CA (25 nM, 3 h). (h) Global levels of RNA 
pol II pS2 or RNA pol II pS5 do not change after treatment with CA by immunoblot 
analysis. Flavopiridol (FP) was used at 300 nM as a positive control (experiment performed 
twice, full scan in Supplementary Figure 1).
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Extended Data Figure 7. Effects of SE-associated gene expression levels on MOLM-14 AML cell 
proliferation
(a) Venn diagram showing overlap between CA upregulated genes and CD14+ master TFs. 
Overlapping genes are listed; SE-associated genes identified by one (purple) or more (red) 
marks in MOLM-14 are indicated. (b) GSEA plot showing positive enrichment of CD14+ 
master TFs upon 3 h CA treatment (MOLM-14 differential expression). (c) Fold-change in 
mRNA copies per cell of selected SE-associated genes upon 3 h treatment with 100 nM CA, 
500 nM I-BET151 or 3 h I-BET151 followed by addition of CA for 3 h (mean ± s.e.m., n=3 
biological replicates, experiment performed twice). (d,h) mRNA expression levels (d) either 
1 day (FLAG-IRF1, FLAG-IRF8) or 3 days (FLAG-CDKN1B, FLAG-FOSL2, FLAG-
ETV6) after induction with doxycycline or (h) 2 days after siRNA electroporation (mean, 
Poisson error, n = 15,000-20,000 technical replicates, experiment performed twice) 
corresponding to Fig. 3f. (e) Immunoblot showing protein levels of CEBPA 4 days after 
siRNA electroporation or 1 day after doxycycline-induced expression (experiment 
performed once) corresponding to Fig. 3f, full scan in Supplementary Figure 1. (f) ChIP-seq 
binding profiles at the FOSL2 and ETV6 loci. (g) mRNA levels of indicated genes in 
MOLM-14 cells expressing FLAG-CDK8 (grey) or FLAG-CDK8 W105M (red) after 3 h 25 
nM CA treatment (mean ± s.e.m., n=3 biological replicates, one of two experiments shown) 
(i) Heatmaps showing BRD4 and CDK8 ChIP-seq on regions depleted of BRD4 >2-fold 
upon I-BET151 treatment for 6 h before and after drug treatment. (j) Effect of 3-day 
treatment with CA, I-BET151 or the combination of CA and I-BET151 on proliferation of 
MOLM-14 (mean ± s.e.m., n=6 biological replicates, one of two experiments shown).
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Extended Data Figure 8. CA inhibits AML progression and CDK8 in vivo and is well-tolerated 
at its efficacious dose
(a) Plasma concentration of CA following single IP administration of 1 mg kg−1 CA to male 
CD-1 mice (mean ± s.e.m., n=3 mice, experiment performed once). (b-g) MV4;11 
disseminated leukaemia study (experiment performed once). (b) Bioluminescence images 
with the median bioluminescence for each treatment group on treatment day 1, showing 
engraftment of MV4;11 leukaemia cells. (c) 30 days after treatment initiation, the mouse 
with the highest, lowest, and median day 29 bioluminescence for each treatment group was 
sacrificed and the spleen weight (p < 0.05) and percentage of MV4;11 cells (mCherry-
positive) in the spleen (p < 0.03) and femur bone marrow (p < 0.02) was determined (n=3 
mice). Dotted purple lines mark the range within 1 s.d. of the mean for healthy 8-week old 
female NSG mice, p-values determined by one-way ANOVA, each treatment vs. vehicle. 
(d) Hematoxylin and eosin staining of day 30 lung, spleen, and bone marrow samples of the 
median mice in (c). Hypercellular alveoli, evidence of leukaemia infiltration, are only 
observable with vehicle treatment. Spleen sample from the vehicle-treated mouse reveals a 
large population of cells with a round nucleus and relatively abundant cytoplasm. Similarly, 
all cells in the vehicle-treated bone marrow have round to oval nuclei and abundant 
cytoplasm, while normal erythroid or myeloid cells are not observed, suggesting that the 
spleen and the bone marrow have been dominated by the leukaemia cells. In contrast, the red 
pulp from the CA-treated mouse spleen shows a heterogeneous population of mature red 
blood cells, nucleated red blood cells, immature myeloid cells and megakaryocytes. The 
bone marrow from a CA-treated mouse also exhibits a mixture of erythroid precursors, 
myeloid precursors, and megakaryocytes. Scale bars, 250 μm. (e) Kaplan-Meier survival 
analysis (n=8 mice, p < 0.0001, log-rank test). (f) Mean body weight ± s.e.m., n=11 mice, 
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for study in Fig. 4b. (g) Complete blood count (CBC) analysis 30 days after first treatment 
for the mice analysed in (c) (n=3 mice). Dotted purple lines mark the range within 1 s.d. of 
mean for healthy 8-week old female NSG mice. (h) Mean body weight ± s.e.m., n=10 mice, 
for study in Fig. 4c (experiment performed once). (i) Immunoblot of NK cell lysate from 
C57BL/6 mice treated as indicated in Fig. 4d. Each lane represents a distinct mouse sample 
with 1 = STAT1 pS727, 2 = STAT1, and 3 = β-actin (experiment performed once, full scan 
in Supplementary Figure 1). (j) Body weight, (k) day 15 CBC, and (l) day 15 blood 
chemistry for healthy CD-1 mice (n=3 mice, experiment performed once) treated with 
vehicle (20% hydroxypropyl-β-cyclodextrin) or 0.16 mg kg−1 CA IP once daily for 15 days. 
(k) RBC, Red Blood Cells (x106 cells/μL); HCT, Hematocrit (%); HGB, Hemoglobin (g/
dL); WBC, White Blood Cells (x103 cells/μL); and PLT, Platelets (x105 platelets/μL). (l) 
CHOL, Total Cholesterol (mg/dL); TRIG, Triglycerides (mg/dL); ALT Alanine 
Aminotransferase (U/L); AST Aspartate Aminotransferase (U/L); ALK, Alkaline 
Phosphatase (U/L); GLU, Glucose (mg/dL); TP Total Protein (g/dL); ALB, Albumin (g/dL); 
GLOB, Globulin (calculated, g/dL); ALB, Albumin (g/dL); A/G, Albumin/Globulin; TBIL, 
Total Bilirubin (mg/dL); BUN, Urea Nitrogen (mg/dL); Ca, Total Calcium (mg/dL); PHOS, 
Phosphorus (mg/dL); Na, Sodium (mEq/L); K, Potassium (mEq/L); Cl, Chloride (mEq/L); 
and Na/K, Sodium/Potassium.
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Extended Data Table 2
CA/CDK8/CCNC ternary complex data collection and refinement statistics.
Data collection and refinement statistics (Molecular replacement)
CDK8/CycC/CA
Data collection
Space group P 21 21 21
Cell dimensions
a, b, c (Å) 70.5, 71.3, 171.3
α, β, γ (°) 90.0, 90.0, 90.0
Resolution (Å) 85.62 (2.40)*
R sym 7.4 (44.8)
I/σI 10.99 (2.66)
Completeness (%) 94.9 (98.6)
Redundancy 2.8 (2.8)
Refinement
Resolution (Å) 85.62 (2.40)
No. reflections 32875 (8656)
Rwork/Rfree 21.7 % / 26.6 %
No. atoms
Protein 5017
Ligand/ion 50
Water 104
B-factors
Protein 32.3
Ligand/ion 56.3
Water 47.5
R.m.s deviations
Bond lengths (Å) 0.009
Bond angles (°) 1.13
*
Highest resolution shell is shown in parenthesis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. CDK8 is asymmetrically loaded at SEs in MOLM-14 cells
(a) Clustering of total ChIP-seq signal of CDK8, MED1, BRD4, H3K27ac, RNA pol II, and 
H3K4me1 on CDK8 positive regions. Each respective cluster is ordered by CDK8 signal. 
The red bar indicates the cluster most highly enriched for the factors listed above. (b) 
Overlap between SEs independently identified by ChIP-seq signal for CDK8, MED1 and 
BRD4 based on the collapsed superset of regions identified by any one factor. (c) ChIP-seq 
binding profiles at the CEBPA locus.
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Figure 2. CA suppresses AML cell proliferation by inhibiting Mediator kinases
(a) CA structure with N,N-dimethylamine red, C5–C9 ethano bridge magenta, C13-methyl 
green and isoquinoline blue. (b) Phosphorylation of the RNA pol II C-terminal domain 
(mean ± s.e.m., n=3 biological replicates, one of two experiments shown, autorad in 
Supplementary Figure 1). (c) Kinome profiling in MOLM-14 lysate (mean, n=2 biological 
replicates, experiment performed once, values < 35% indicate no change). (d) CA binding 
pocket of CDK8 from CA-CDK8-CCNC crystal structure (semi-transparent surface; CA in 
gold, CDK8 in grey) with contact residues and CA in stick representation. Dotted red lines 
indicate H-bonds. (e) Effect of CA on growth of indicated cell lines (mean ± s.e.m., n=3 
biological replicates, one of two experiments shown). (f) Sensitivity of MOLM-14 cells to 
CA upon expression of indicated kinases (mean ± s.e.m., n=3 biological replicates, one of 
two experiments shown). (g) Immunoblot showing IFN-γ-stimulated STAT1 S727 
phosphorylation in MOLM-14 cells expressing indicated kinases and treated with CA (one 
of two experiments shown, full scan in Supplementary Figure 1).
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Figure 3. CA disproportionately increases transcription of SE-associated genes
(a-b) GSEA plots show that genes upregulated upon 3h CA treatment of MOLM-14 cells 
are significantly enriched in (a) MOLM-14 SE-associated genes (SE genes) and (b) genes 
downregulated by IBET-151 ≥2-fold in MOLM-13 cells. Red bars in b indicate H3K27ac 
SE genes in MOLM-14 cells in GSEA leading edge (22 genes, Fisher's exact test, p = 1.2 × 
10−3). (c) Scatterplot of false discovery rate (FDR-q) versus normalized enrichment score 
(NES) for indicated gene sets evaluated by GSEA (n = 3,867), including C2 of MSigDB. (d) 
Cumulative distribution plots of RNA pol II TR. (e) Change in mRNA copy number/cell of 
selected SE genes after 3 h treatment (red and blue bars) or after 6 h I-BET151 treatment 
with CA treatment for the final 3 h (green bar) (mean ± s.e.m., n=3 biological replicates, one 
of two experiments shown). (f) Effect of change in expression of selected SE genes on 
MOLM-14 cell growth (mean ± s.e.m., with n=3 biological replicates for siETV6 and 
siFOSL2 and 6 for other siRNA knockdowns, 24 for FLAG-CEBPA and 12 for other 
inducible expressions, one of 2-6 experiments shown). (g) GSEA of SE genes in CA-treated 
cells. Regions of CDK8 and H3K27Ac co-enrichment identify SE genes in each cell line.
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Figure 4. CA inhibits AML progression and CDK8 in vivo
(a) Bioluminescent images of mice bearing MV4;11 leukaemia cells. Mouse with median 
bioluminescence shown, treatment as in (b). Color scale 1.00×106 to 1.00×108. (b) Mean ± 
s.e.m., n=11 mice; p < 0.0001 for both doses on day 33 vs. vehicle, two-way ANOVA. (c) 
Mice harbouring SET-2 AML xenograft tumours and treated as indicated. Mean ± s.e.m., 
n=10 mice; 71% tumour growth inhibition on day 33, p < 0.0001, two-tailed t-test. (d) 
Densitometric analysis of STAT1 pS727 in NK cells isolated from the spleen of C57BL/6 
mice treated with CA or vehicle (n=3 mice), STAT1 pS727 normalized to actin, p = 0.011 
for 0.625 mg kg−1, one-way ANOVA, experiment performed once.
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